NIH grants IDT 10-year vaccine manufacturing contract by Angus Liu Tuesday, October 23, 2018 If the German contract manufacturer delivers all projects over the 10-year course, it could receive up to $80 million.
FluGen’s broadly protective flu vaccine clears phase 1 by Angus Liu Tuesday, October 9, 2018 Through an ongoing "challenge" study, FluGen hopes to see whether the nasal vaccine can fight off the flu virus that doesn't match its own.
Scientists weigh Zika challenge study: report by Eric Sagonowsky Tuesday, September 18, 2018 Zika vaccine research continues in the absence of a large-scale outbreak, but a shortage of cases is making it hard to test for efficacy.
Zika, VBI Vaccines and more—News of Note by Eric Sagonowsky Tuesday, August 21, 2018 Here is some other vaccine news of note for the week.
Immune responses from J&J's HIV shot last 1 year: study by Eric Sagonowsky Tuesday, July 24, 2018 Johnson & Johnson's "mosaic" HIV vaccine regimen elicited immune responses one year after the final shot.
Vaccination rates, RSV vaccine and more—News of Note by Angus Liu Wednesday, June 20, 2018 Here is some other vaccine news of note for the week.
U.K. research hub, Bavarian Nordic and more—News of Note by Eric Sagonowsky Wednesday, June 6, 2018 Here is some other vaccine news of note for the week.
ILiAD, Emergex and more—News of Note by Eric Sagonowsky Wednesday, May 16, 2018 Here is some other vaccine news of note for the week.
Inovio's early-stage HIV vaccine delivers lasting immune responses by Eric Sagonowsky Tuesday, May 15, 2018 Inovio's HIV vaccine is in early-stage development, but the company reported immune responses induced by the shot that lasted at least six months.
BiondVax, NIAID kick off phase 2 universal flu shot study in U.S. by Eric Sagonowsky Wednesday, April 11, 2018 BiondVax enrolled its first patient in a phase 2 U.S. study of its universal flu vaccine, which aims to fight off all strains of the virus at the same time.
